Guizhou Bibang Pharmaceutical Co., Ltd. 2025 Annual Report Summary Securities Code: 002390 Securities Abbreviation: Bibang Pharmaceutical Announcement No.: 2026-007 Guizhou Bibang Pharmaceutical Co., Ltd. 2025 Annual Report Summary I. Important Notice This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial condition, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission. All directors attended the board meeting that reviewed this report. Non-Standard Audit Opinion Notice □ Applicable Not Applicable Board of Directors' Review of Profit Distribution Plan or Capital Reserve Transfer to Share Capital for the Reporting Period ☑ Applicable Not Applicable Is Capital Reserve Transferred to Share Capital? □ Yes No The profit distribution plan reviewed and approved by the company's board of directors is as follows: Based on the total share capital of 1,896,406,328 shares, after deducting the 47,445,540 shares repurchased by the company's dedicated securities account for repurchase, a cash dividend of 0.6 yuan (tax inclusive) per 10 shares will be distributed to all shareholders. No bonus shares will be issued (tax inclusive). Capital reserve will not be transferred to share capital. Board Resolution on Preferred Stock Profit Distribution Plan for the Reporting Period □ Applicable Not Applicable II. Company Basic Information
- Company Profile Stock Abbreviation Bibang Pharmaceutical Listed Stock Exchange Shenzhen Stock Exchange Stock Code 002390 Contacts and Contact Information Name Board Secretary Securities Affairs Representative Chen Chuan Chen Chuan Office Address 6th Floor, Ke Kai No. 1, Section 3, Xin Tian Avenue North Section, Wudang District, Guiyang City, Guizhou Province 6th Floor, Ke Kai No. 1, Section 3, Xin Tian Avenue North Section, Wudang District, Guiyang City, Guizhou Province Fax 0851-88660280 0851-88660261 Telephone 0851-88660261 0851-88660261 Email cc@xinbang.com cc@xinbang.com
- Summary of Main Business and Products (1) Main Business and Business Model During the reporting period, the company's main business remained unchanged, as follows: [Chart: Business Structure Diagram] ① Medical Services
- Summary of Main Accounting Data and Financial Indicators (1) Main Accounting Data and Financial Indicators for the Past Three Years Does the company need to retrospectively adjust or restate previous year's accounting data? □ Yes No Unit: RMB 2025 Year-end 2024 Year-end Year-on-year Change 2023 Year-end Total Assets 8,590,502,404.79 9,028,336,478.89 -4.85% 9,244,971,150.19 Net Assets Attributable to Shareholders of the Parent Company 6,789,858,736.90 6,710,056,421.59 1.19% 6,852,401,324.17 Operating Revenue 5,619,564,836.88 6,032,262,052.57 -6.84% 6,460,841,315.46 Unit: RMB 2025 2024 Year-on-year Change 2023 Net Profit Attributable to Shareholders of the Parent Company 120,285,770.05 101,381,622.75 18.65% 287,232,798.94 Net Profit Attributable to Shareholders of the Parent Company After Deducting Non-Recurring Gains and Losses 87,111,687.33 165,318,585.59 -47.31% 267,902,516.17 Net Cash Flow from Operating Activities 732,530,622.51 634,968,962.59 15.36% 790,618,030.35 Basic Earnings Per Share (RMB/Share) 0.0634 0.0533 18.95% 0.1483 Diluted Earnings Per Share (RMB/Share) 0.0634 0.0533 18.95% 0.1483 Weighted Average Return on Equity 1.79% 1.50% 0.29% 4.19% (2) Quarterly Main Accounting Data Unit: RMB First Quarter Second Quarter Third Quarter Fourth Quarter Operating Revenue 1,441,207,780.35 1,403,817,491.33 1,421,260,016.43 1,353,279,548.77 Net P